BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Covington
US Department of Justice
Farmers Insurance
US Army
Cantor Fitzgerald
Merck
Citi
McKesson
Dow

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,671,032

« Back to Dashboard

Which drugs does patent 7,671,032 protect, and when does it expire?

Patent 7,671,032 protects OLYSIO and is included in one NDA.

This patent has sixty-six patent family members in thirty-one countries.
Summary for Patent: 7,671,032
Title:HCV NS-3 serine protease inhibitors
Abstract: Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site. ##STR00001##
Inventor(s): Rosenquist; Asa (Huddinge, SE), Thorstensson; Fredrik (Linkoping, SE), Johansson; Per-Ola (Linkoping, SE), Kvarnstrom; Ingemar (Linkoping, SE), Samuelsson; Bertil (Huddinge, SE), Wallberg; Hans (Huddinge, SE)
Assignee: Medivir AB (Huddinge, SE)
Application Number:10/572,349
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,671,032

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen Prods OLYSIO simeprevir sodium CAPSULE;ORAL 205123-001 Nov 22, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,671,032

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0400199Jan 30, 2004
Sweden0401288May 19, 2004
Sweden0402562Oct 22, 2004
PCT Information
PCT FiledJanuary 28, 2005PCT Application Number:PCT/SE2005/000097
PCT Publication Date:August 11, 2005PCT Publication Number: WO2005/073195

Non-Orange Book US Patents Family Members for Patent 7,671,032

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,608,590 HCV NS-3 serine protease inhibitors ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,671,032

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 047793 ➤ Subscribe
Argentina 048401 ➤ Subscribe
Argentina 104445 ➤ Subscribe
Austria 448243 ➤ Subscribe
Austria 461209 ➤ Subscribe
Australia 2005207815 ➤ Subscribe
Australia 2005207816 ➤ Subscribe
Brazil PI0506945 ➤ Subscribe
Brazil PI0506948 ➤ Subscribe
Canada 2552317 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fish and Richardson
UBS
Accenture
Express Scripts
Novartis
Merck
McKesson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot